Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of LY3819469 in adults with elevated lipoprotein(a)
jRCT2031220412Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of lepodisiran in hyperlipoproteinemia and dyslipidemia (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent change from baseline in time-averaged lipoprotein(a) [Lp(a)]. Started Nov 2022; status: active, not recruiting.
02
Drugs
lepodisiran
03
Conditions
hyperlipoproteinemiadyslipidemia
Beyond the preview
Go deeper on jRCT2031220412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220412.